Feedback / Questions
ALTA-2618 - Alterome Therap
https://www.businesswire.com/news/home/20241030626999/en/Alterome-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Study-of-ALTA2618-in-AKT1-E17K-mutant-solid-tumors-AKTive-001
Oct 30, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next